Rosuvastatin in older patients with systolic heart failure.

By M. Clearfield. Current Atherosclerosis Reports, 2009

832 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/f653662e81aab984656fe5d6bd40078cadcfff28

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Surgery

Citations in the corpus

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “However, 2 large RCTs have demonstrated that rosuvastatin has neutral effects on long-term outcomes in patients with chronic HFrEF when added to standard GDMT.(537,538) At present, statin therapy should not be prescribed primarily for the treatment of HF to improve clinical outcomes.”
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “Rosuvastatin did not reduce the primary composite mortality/ morbidity endpoints in two large RCTs in patients with HF with or without IHD, but it also did not increase risk, and may have reduced, hospitalizations.(205,457) Therefore there is no evidence to recommend the initiation of statins in mos”
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “In the 4 RCTs reviewed that specifically addressed statin treatment in these groups, there were individuals with and without heart disease (86-89).”
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “Observational studies are subject to confounding, and treatment with statins should not be started in patients with moderate to severe HF [New York Heart Association (NYHA) classification III– IV].36,39 However, there is no evidence for harm in patients on statin treatment after the occurrence of HF”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “The number of hospitalizations for cardiovascular causes was reduced significantly.(127) † The value of statins in HF patients with a non-ischaemic aetiology is unknown.”
Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (2014, background): “In the 4 RCTs reviewed that specifically addressed statin treatment in these groups, there were individuals with and without heart disease (86-89).”
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “Both for GDMT and other recommended drug treatment regimens, the reader is advised to confirm dosages with product insert material and to evaluate carefully for contraindications and drug-drug interactions.”
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials (2015, methodology): “26,27 Information about plasma glucose and insulin concentrations, BMI, waist circumference, and waist:hip ratio was unavailable from the trials.”